New drug combo aims to slow aggressive brain tumors
NCT ID NCT07215910
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 29 times
Summary
This study tests whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation can slow tumor growth better than chemo alone in people with a specific, aggressive brain tumor (grade 3 IDH-mutated astrocytoma). About 408 newly diagnosed patients will take part. The goal is to see if the combination extends the time before the tumor progresses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 3 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.